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Summary
G2A is a lymphocyte-expressed G protein-coupled receptor whose genetic ablation results in the development of autoimmu-
nity. Using HSV-TK reporter gene directed positron emission tomography (PET), we demonstrate that prior to any indication
of the onset of illness, mice transplanted with BCR-ABL transduced G2A-deficient bone marrow harbor expanded popula-
tions of leukemic cells compared to recipients of wild-type bone marrow. The target cell type and anatomical locations
of leukemia development are indistinguishable in animals transplanted with G2A/ or G2A/ cells. Shorter disease
latency in the G2A-deficient background is associated with an increased rate of cellular expansion. PET can be successfully
applied to the temporal and spatial analysis of Bcr-Abl driven leukemic progression and should have utility for the study
of other leukemias and lymphomas.
Introduction mouse populations is governed by a complex set of genetic
traits which includes modifier loci (Balmain, 2002; Van Dyke
The presence of identical disease associated genetic mutations and Jacks, 2002). Several modifier loci have subsequently been
within the human population often results in quite different indi- mapped further to define individual modifier genes. Notable
vidual outcomes with respect to susceptibility, latency, clinical examples are the association of genetic polymorphisms within
features, and severity (Houlston and Tomlinson, 1998). Similarly, the genes encoding secretory phospholipase A2 (sPLA2) and the
mice inheriting the same genetic mutation predisposing to cer- p16INK4a cyclin-dependent kinase inhibitor products which confer
tain diseases may show very different outcomes, attributed to strain dependent susceptibility to intestinal tumorigenesis and
differences in genetic background and the influence of one or plasmacytoma induction, respectively (Cormier et al., 1997;
more modifier genes. Identification of these modifiers provides Dietrich et al., 1993; Mock et al., 1993; Zhang et al., 2001).
Classical approaches to study the impact of candidate mod-important insights into developmental and physiological pro-
cesses, and genetic studies remain the most powerful tool with ifier genes upon cancer progression in animal models are limited
by the requirement for autopsy to evaluate tumor burden, whichwhich to do so (Nadeau, 2001).
The development of cancer results from the progressive necessitates manual exploration of multiple anatomical sites for
tumor incidence and imposes a requirement for large experi-accumulation of mutations which ultimately lead to the deregula-
tion of normal cellular growth, survival, and differentiative mech- mental groups to control for intersubject variability. Live imaging
of cancer progression by techniques such as positron emissionanisms. Cancer susceptibility and progression in human and
S I G N I F I C A N C E
Expression of the BCR-ABL tyrosine kinase is the initiating etiological event in a subset of human lymphoid leukemias. We have
developed a transplantation model for BCR-ABL induced lymphoid tumorigenesis utilizing positron emission tomography to study
the modification of leukemogenic progression caused by loss of a novel BCR-ABL transcriptional target, the G protein-coupled
receptor G2A. This receptor represents a class of lymphoid growth regulators which modifies the action of oncogenic signals from
BCR-ABL. This model allows the kinetic and spatial examination of leukemia initiation and progression in individual animals and the
separate contribution of proliferative expansion and leukemic dissemination to these processes. We believe that this system can
be further applied to more thoroughly evaluate therapeutic agents targeting specific pathways deregulated by BCR-ABL and other
leukemia specific oncoproteins.
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tomography (PET) would circumvent these problems and allow of signaling and biological properties of G2A (Kabarowski et al.,
sequential kinetic and spatial measurements of tumor develop- 2000; Le et al., 2001; Weng et al., 1998), this may be due to
ment in individual animals. altered leukemic cell migration/homing or more rapid cell-cycle
BCR-ABL is a chimeric tyrosine kinase resulting from a re- progression. To address this issue, we utilized positron emission
ciprocal translocation of chromosomes 22 and 9, producing a tomography (PET) based on coexpression of the HSV-TK re-
fusion product from the cellular genes encoding BCR and c-ABL porter gene to evaluate tumor extent and sites of tumor growth
(Chopra et al., 1999; Nowell and Hungerford, 1960; Rowley, in a kinetic manner for individual mice transplanted with BCR-
1973). In patients, three fusion products are detected, each ABL transduced wild-type or G2A-deficient bone marrow cells.
differing in the amount of BCR encoded sequences they contain. PET is a nuclear imaging technique that combines high im-
P185 BCR-ABL is associated with 15%–25% of patients with age resolution with a quantitative method for detecting the loca-
aggressive, poor prognostic acute lymphoblastic leukemia tion and levels of radiotracer accumulation in living subjects
(ALL), and P210 BCR-ABL is associated with 95% of cases of
(Cherry and Gambhir, 2001). Bone marrow cells were trans-
chronic myeloid leukemia (CML). The more recently identified
duced with a bicistronic retroviral vector containing BCR-ABLP230 BCR-ABL is associated with a mild chronic neutrophilic
and the HSV-TKsr39 allele as a PET reporter gene whose prod-leukemia (Saglio et al., 1990; Sawyers, 1999). The etiology of
uct will sequester positron-emitting reporter probes (HerschmanBCR-ABL leukemia has received considerable attention due
et al., 2000). The selective retention of the PET probe in targetto the tremendous efficacy with which the ABL kinase inhibitory
tissues is then imaged in living animals, allowing one to generatedrug Gleevec (STI571) induces disease remission in CML pa-
consecutive, quantitative, and spatial measurements showingtients (Druker and Lydon, 2000). However, recent reports of
the dynamic evolution of tumor development in a noninvasiveclinical resistance to this drug developing in a proportion of
fashion. We found that prior to any indication of overt illnesspatients have underlined the need for further studies of its patho-
(preleukemic phase), mice transplanted with G2A-deficient bonepharmacological actions in vivo (Gorre et al., 2001).
marrow harbor significantly expanded populations of BCR-ABLClinical studies and experimental animal models are consis-
tent with BCR-ABL serving as the initiating event in the transfor- positive B lymphoid progenitor cells compared to recipients of
mation/leukemogenic process and with additional genetic, and wild-type bone marrow. However, the spatial pattern of disease
perhaps epigenetic, events being required for progression to development is similar in all animals, suggesting that the de-
overt malignancy (Gishizky and Witte, 1992; Mitelman, 1993; creased latency for leukemogenesis in the context of G2A abla-
Sawyers, 1999). The latency for Pre-B lymphoma induction by tion results primarily from increased leukemic cell expansion,
the related viral oncoprotein vABL has been shown to be highly rather than altered cellular migration and sites of leukemic dis-
mouse strain dependent (Abelson and Rabstein, 1970; Risser semination. These results indicate that G2A is a negative mod-
et al., 1978; Rosenberg and Baltimore, 1976). While 90% of ifier of lymphoid leukemogenesis induced by BCR-ABL in vivo
neonatal BALB/c mice injected intraperitoneally with Abelson
acting primarily to affect cell proliferation or viability.
Murine Leukemia Virus (Abl-MLV) develop lymphomas with a
mean latent period of 92 days, only 36% of B6 mice develop
Resultsa similar malignancy with a protracted latent period of 120 days
(Risser et al., 1985). This implies that genetic context plays a
Effect of G2A ablation on P185 BCR-ABL-mediatedmajor role governing the susceptibility to disease induced by
transformation in vitrothe ABL family of oncoproteins.
The transformation activities of P185 BCR-ABL include the abil-We have previously identified a novel G protein-coupled
receptor (GPCR), named G2A, in a search for genes transcrip- ity to eliminate growth factor requirements of bone marrow B
tionally regulated by P185 BCR-ABL (Weng et al., 1998). G2A cell progenitors for survival and proliferation (McLaughlin et al.,
belongs to a subfamily of GPCR with ligand specificities for 1987, 1989). As G2A is transcriptionally induced in B lymphoid
structurally related lysophospholipids (Im et al., 2001; Kabarow- progenitors by BCR-ABL during this transformation process
ski et al., 2001; Xu et al., 2000; Zhu et al., 2001). G2A is ex- and suppresses its transformation potency when overexpressed
pressed predominantly in hematopoietic cells including T and (Weng et al., 1998), we wished to determine whether induction
B lymphocytes. Forced overexpression of G2A antagonizes the of G2A expression under physiological conditions plays a role
transformation potency of BCR-ABL in vitro (Weng et al., 1998). in BCR-ABL in vitro transformation.
G2A-deficient mice develop a late onset, slowly progressive Retrovirally mediated expression of BCR-ABL in primary
autoimmune syndrome, demonstrating a critical role for G2A in
bone marrow results in transformation of Pro/Pre-B cells in
controlling peripheral lymphocyte homeostasis, T lymphocyte
stromal cell-dependent cultures (McLaughlin et al., 1987). Theproliferation and autoimmunity (Le et al., 2001). These observa-
growth rate of Pre-B cells from infected marrow can be directlytions support the notion that G2A negatively regulates lympho-
monitored and quantitatively reflects BCR-ABL tyrosine kinasecyte growth responses in the context of sustained proliferative
activity and transformation potency (Lugo et al., 1990). To deter-signals.
mine the effect of G2A ablation on P185 BCR-ABL-mediatedIn this study, we have sought to determine by a direct genetic
transformation in vitro, bone marrow cells from wild-type andtest whether loss of G2A function modulates the efficiency of
G2A-deficient mice were infected with a retrovirus encodingBCR-ABL leukemogenesis. We found that mice transplanted
green fluorescent protein (GFP) plus P185 BCR-ABL (MSCV-with BCR-ABL transduced G2A-deficient bone marrow cells
GFP-IRES-BCR-ABL). Liquid cultures were plated in triplicateexhibit earlier tumor onset, more rapid tumor progression, and
and monitored for Pre-B cell outgrowth at various time points.shorter survival times compared to those receiving BCR-ABL
transduced wild-type bone marrow. Based on our knowledge All infected cultures, irrespective of genotype, gave rise to mor-
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phologically typical transformed Pro/Pre-B lymphocytes (Fig-
ures 1A and 1B). Since forced overexpression of G2A at high
levels suppressed the transformation potency of BCR-ABL in
fibroblasts and decreased lymphoid transformation (Weng et
al., 1998), we predicted that lack of G2A function might enhance
BCR-ABL transformation potency in long-term bone marrow
culture (LTBMC). Surprisingly, cell counts performed on these
cultures revealed that both wild-type and G2A-deficient Pre-B
lymphocytes expanded at similar rates (Figure 1C). These results
indicate that G2A-deficient bone marrow cells are equally sus-
ceptible to P185 BCR-ABL-mediated transformation in vitro,
with comparable rates of cellular expansion compared to wild-
type bone marrow cells.
Loss of G2A function accelerates lymphoid
leukemogenesis induced by P185 BCR-ABL
We sought to further characterize the biological properties of
G2A in vivo as a more stringent test of its physiological role in
BCR-ABL transformation. Although the absence of G2A expres-
sion has no effect on the transformation potency of P185 BCR-
ABL in vitro, G2A may deregulate a biological process in vivo
that is not adequately recapitulated in long-term bone marrow
cultures. In addition, some genetic alterations that result in
transformation of cultured cells do not elicit tumorigenesis in
mice, and many mutations that cause dramatic effects in vivo
induce no observable phenotypes in vitro. For example, while
the absence of p53 has no effect on the frequency of bone
marrow transformation by Abl-MLV in vitro, p53-deficient mice
infected with Abl-MLV develop lymphoid tumors more rapidly
compared to those which retain p53 function (Unnikrishnan et
al., 1999).
P185 BCR-ABL was used to induce lymphoid leukemogene-
sis in a retroviral infection and transplantation model (Afar et
al., 1997; Lim et al., 2000). This model was chosen because it
is highly reproducible and the kinetics of leukemia induction are
well established. In order to avoid host immune responses to
the human P185 BCR-ABL protein, we used SCID mice as
recipients of transduced bone marrow cells (Stripecke et al.,
1998).
Wild-type or G2A-deficient bone marrow cells were infected
with retroviruses encoding GFP plus BCR-ABL (MSCV-GFP-
IRES-P185 BCR-ABL) followed by transplantation of transduced
cells into sublethally irradiated C.B-17SCID/SCID mice. In four inde-
pendent experiments (25 mice per group total), we consistently
observed that SCID mice transplanted with infected G2A-defi-
Figure 1. Absence of G2A does not affect in vitro transformation efficiency
cient bone marrow cells displayed a marked acceleration of of P185BCR-ABL
leukemia development. These animals began to exhibit signs Bone marrow cells from G2A-deficient and wild-type littermates were in-
of illness characterized by hind limb paralysis, hunchback, fected with MSCV-GFP-IRES-P185 BCR-ABL retroviruses and plated in liquid
culture. A: Flow cytometric analysis of G2A-deficient (left) and wild-typetachypnea, and eventually death 19 days following transplanta-
(right) transformed bone marrow cells. BP-1 is a surface marker for Pre/tion, with 50% mortality at 33 days. By 50 days, all animals
Pro-B cells (Cooper et al., 1986). Proportions of cells in each quadrant are
transplanted with BCR-ABL transduced G2A-deficient bone indicated as percentages. B: Photomicrographs (magnification 40) of
marrow cells had succumbed to leukemia. In contrast, all mice G2A-deficient (left) and wild-type (right) transformed Pre-B lymphocytes.
C: Pre-B cell growth was monitored at the indicated timepoints. Meanreconstituted with BCR-ABL transduced wild-type bone marrow
cell count values from triplicate data sets are presented with standardcells survived to day 31, with only 5% mortality by 33 days, and
deviations. Cultures reached confluency around 2  107 cells/per 3 ml
55% mortality at 51 days (Figure 2). All animals were sacrificed culture.
shortly thereafter. These data demonstrate that although initial
in vitro transformation events elicited by P185 BCR-ABL are
not affected by loss of G2A function, loss of G2A function po-
tentiates the development of P185 BCR-ABL induced leukemia
in vivo.
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Figure 2. Acceleration of P185 BCR-ABL mediated lymphoid leukemogene-
sis in the absence of G2A
Bone marrow cells from either G2A-deficient or wild-type mice were in-
fected with MSCV-GFP-IRES-P185 BCR-ABL retroviral stocks. 1  106 infected
cells were intravenously injected into the tail vein of sublethally irradiated
SCID mice. Mice were monitored for signs of illness daily. Experiment was
terminated after two months. Leukemic diagnosis of newly deceased mice
was based on gross, microscopic, and FACS analyses. Survival data are
presented as a Kaplan-Meyer plot.
Mice transplanted with P185 BCR-ABL transduced
wild-type and G2A-deficient bone marrow develop
leukemias of identical phenotype
To determine if loss of G2A function alters BCR-ABL mediated
leukemogenesis by affecting the target cell specificity for trans-
formation, we examined whether P185 BCR-ABL-induced leu-
kemias that developed in wild-type and G2A-deficient back-
grounds had similar phenotypes. We performed gross clinical
and cellular analyses of overtly ill mice. These studies revealed
comparable pathology, independent of genetic status (Figure
3A). Disease symptoms were uniform regardless of genotype,
typically including high peripheral white blood cell counts,
splenomegaly, bone marrow involvement, asymmetric lymph
node enlargement, and hind limb paralysis. In all cases, histo-
chemical analysis of affected mice showed high grade lympho-
blastic lymphomas that were morphologically and histologically
indistinguishable in mice receiving BCR-ABL transduced wild-
type or G2A-deficient bone marrow cells (Figures 3B–3D). RT-
PCR analysis of RNA from G2A-deficient leukemic cells derived
Figure 3. Comparison of the leukemic histopathology in recipients of wild-from bone marrows and spleens of multiple animals failed to
type and G2A-deficient bone marrow cells
detect the expression of G2A mRNA. However, its expression
A: Enlarged spleens from typical leukemic mice reconstituted with G2A-is abundant in wild-type leukemic cells (Figure 3E).
deficent bone marrow (left) and its wild-type counterpart (right). B–D: photo-
To determine the lineage and developmental stage of leuke- micrographs (magnification 400) of Giemsa/Wright stained G2A-deficient
(left) and wild-type (right) leukemic cells derived from spleens (B), bonemias arising in recipients, tumor cells were isolated from bone
marrow (C), and peripheral blood smears (D). E: RT-PCR analysis using G2A-marrow, spleen, lymph nodes, and peripheral blood, and ana-
specific primers (Weng et al., 1998) of total RNA isolated from G2A-deficient
lyzed by flow cytometric analysis of specific surface markers. (G2A/) or wild-type (G2A/) leukemic cells derived from bone marrow
Leukemic cells of both genotypes in 100% of terminally ill mice (BM) or spleen (SPL).
were uniformly GFP-positive and positive for B220 and BP-1
markers, consistent with a Pro/Pre-B cell phenotype (Cooper
et al., 1986; Hardy and Hayakawa, 2001) (Figures 4A–4C). In tion enhances BCR-ABL mediated leukemogenesis without af-
addition, leukemic cells were negative for Thy1.2, Ter119, and fecting the target cell for transformation.
Gr-1 markers. Thus, the combination of histological and flow
cytometric analyses indicate that mice reconstituted with BCR- Kinetic analysis of leukemia development by PET
ABL transduced bone marrow cells of either genotype succumb We previously reported that ectopic expression of G2A in heter-
ologous cell types delays cell-cycle progression through G2/Mto similar Pro/Pre-B cell leukemias. Therefore, loss of G2A func-
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negative regulation of proliferation and integration of extracellu-
lar signals with cytoskeletal reorganization and cell motility.
Thus, although the cellular target for tumor induction by BCR-
ABL is similar in both G2A-deficient and wild-type backgrounds,
G2A ablation could have a profound effect on the rate of prolifer-
ation, migratory behavior, or anatomical colonization of leuke-
mic cells in vivo. We therefore examined the contribution of
altered leukemic cell migration/homing versus cell-cycle pro-
gression to the earlier mortality associated with loss of G2A
function.
We exploited PET technology to follow kinetic and spatial
characteristics of leukemia development in individual mice
transplanted with BCR-ABL transduced wild-type or G2A-defi-
cient bone marrow cells. To achieve this goal, we coupled the
expression of P185 BCR-ABL to that of the Herpes Simplex
Virus (HSV)-1sr39TK PET reporter gene in a bicistronic retroviral
vector (MSCV-TK-IRES-P185 BCR-ABL) (Figure 5A). HSV-
1sr39TK is a specific mutant form of Herpes Simplex Virus
Thymidine Kinase (TK) that has a significantly higher affinity for
the acycloguanosines (Gambhir et al., 2000). To demonstrate
the ability to image transplanted MSCV-TK-IRES-P185 BCR-
ABL transduced wild-type bone marrow cells in recipient SCID
mice, we compared SCID mice transplanted with either MSCV-
GFP-IRES-P185 BCR-ABL or MSCV-TK-IRES-P185 BCR-ABL
transduced bone marrow cells (Figure 5A). Twenty-five days
following transplantation, recipient SCID mice were injected in-
travenously with 200 Ci 9-(4-[18F]-fluoro-3 hydroxymethylbutyl)
guanine (FHBG) and subjected to whole-body microPET scan.
Serial 3D microPET scans were performed dorsoventrally with
data collection in 64 planes of section, and mice were also
X-rayed for visualization of skeletal landmarks following the final
scan. Physiological hepato-biliary and renal excretion of FHBG
is seen in several planes in all recipient animals (Figures 5B and
5C). Therefore, interpretations of PET scan are most informative
for the thorax, neck, head, and limbs. Multiple consecutive sec-
tions at the thoracic spine level of a TK-BCR-ABL-positive leuke-
mic animal are shown in Figure 5D to demonstrate the 3D resolu-
tion of the microPET technique.
SCID mice were transplanted with wild-type or G2A-defi-
cient bone marrow cells transduced with MSCV-TK-IRES-P185
BCR-ABL retroviruses. 9, 16, 23, and 30 days following trans-
plantation, mice were injected intravenously with 200 Ci FHBG
and subjected to whole-body microPET scan. Serial 3D micro-
PET scans were performed dorsoventrally with data collection
in 64 planes of section. We successfully imaged highly specific
regional expansion of B lymphoid cells in these mice at timesFigure 4. Flow cytometric analysis of wild-type and G2A-deficient leukemic
when few leukemic cells were detectable in their peripheralcells
blood. Representative images derived from data collected inFlow cytometric analysis to determine the lineage and developmental
stage of leukemias. Spleen (A), bone marrow (B), and peripheral blood (C) three sectional planes of multiple (2–5) animals per group at
were harvested from typical leukemic mice transplanted with G2A-deficient each timepoint are presented (Figures 6A–6D). Although no PET
(left) or wild-type (right) bone marrow. All leukemic cells were uniformly signal was detected 9 days following transplantation of either
GFP-positive and positive for B220 and BP-1, which are markers for Pro/Pre-B
BCR-ABL transduced G2A-deficient or BCR-ABL transducedcell. Proportions of cells in each quadrant are indicated as percentages.
wild-type bone marrow cells (Figure 6A), strong signals were
observed in recipients of BCR-ABL transduced G2A-deficient
bone marrow cells in the spine and calvaria at day 16. At the
same time, no signal was observed in recipients of BCR-ABL(Weng et al., 1998). Consistent with this observation, G2A-defi-
transduced wild-type bone marrow (Figure 6B). By day 23, TKcient T cells are hyperproliferative to a variety of stimuli (Le et
G2A-deficient cells had accumulated in the cervical lymphal., 2001). In addition, we have established the coupling of G2A
nodes, sternum, and femur/tibia as indicated by intense signalsto G13, leading to activation of RhoA and actin stress fiber
detected in these areas (Figure 6C). In contrast, at this timepoint,formation in fibroblasts (Kabarowski et al., 2000). These obser-
vations implicate a number of possible roles for G2A, including a weak signal was detected in the thoracic spine area of recipi-
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ents of BCR-ABL transduced wild-type bone marrow cells. a dramatic effect on the kinetics of leukemogenesis in vivo,
loss of G2A function has no discernable effect on B lymphoidThirty days posttransplantation, TK wild-type leukemic cells
eventually extended to the calvaria, cervical lymph nodes, ster- transformation by BCR-ABL in LTBMCs in vitro. These results
suggest that G2A regulates a biological process in vivo that isnum, and femur (Figure 6D). However, at this timepoint, the PET
signal was weaker compared to that observed in recipients of not adequately recapitulated in long-term bone marrow cultures.
Although the precise molecular basis underlying the modifi-BCR-ABL transduced G2A-deficient bone marrow cells.
These observations indicate that the initiation and progres- cation of BCR-ABL mediated leukemogenesis by G2A is pres-
ently unknown, several possible explanations can be proposedsion of disease is significantly accelerated in mice receiving
MSCV-TK-IRES-P185 BCR-ABL transduced G2A-deficient based on our knowledge of the biological properties of this
receptor. We recently identified the inflammatory lysophospho-bone marrow cells. However, the pattern and anatomical loca-
tions of leukemia development were indistinguishable in all ani- lipid lysophosphatidylcholine (LPC) as a ligand for G2A (Kaba-
rowski et al., 2001), and it is possible that high concentrationsmals tested, suggesting that increased mortality of mice trans-
planted with BCR-ABL transduced G2A-deficient bone marrow of LPC or other cofactors in vivo work through G2A to limit
lymphocyte growth. G2A may thereby constitute a transcription-is associated with increased cellular expansion and resultant
leukemic burden, rather than an altered route of leukemic dis- ally regulated negative feedback loop utilized by cells as a global
protective mechanism to balance sustained proliferative stimuli.semination and organ/tissue involvement.
Transcriptional induction of Smad 7 by TGF and Suppressor
Of Cytokine Signaling (Socs) proteins in reponse to cytokineDiscussion
receptor activation serve as paradigms for the activation of a
negative growth regulatory pathway by positive growth signalsThe ability to noninvasively visualize tumor development in ani-
mal models has become a major area of cancer research. We (Krebs and Hilton, 2001; Nakao et al., 1997).
It is possible that transcriptional induction of G2A in BCR-have developed a novel transplantation model for BCR-ABL
induced leukemia in which expression of BCR-ABL is coupled ABL expressing B lymphoid progenitors elicits signals that spe-
cifically antagonize one or more of those mediating key patho-to that of the Herpes Simplex Virus 1sr39 thymidine kinase
PET reporter gene. This model allows the kinetic and spatial physiological processes downstream of BCR-ABL. In this re-
spect, the ability of BCR-ABL to decrease the adhesive capacityexamination of leukemia initiation and progression in individual
animals and the separate contribution of proliferative expansion of hematopoietic progenitors to stromal elements is believed
to contribute to their escape from normal growth inhibitory in-and leukemic dissemination to these processes. Our ability to
successfully monitor leukemia development in individual recipi- fluences within the bone marrow microenvironment and abnor-
mal homing to extramedullary sites (Gordon et al., 1987a,ent mice by microPET imaging validates the use of this model of
BCR-ABL induced leukemia for the study of candidate modifiers 1987b). This property is associated with the ability of BCR-ABL
to associate with the actin cytoskeleton (McWhirter and Wang,and effector pathways. We therefore applied this model to ad-
dress whether the G protein-coupled receptor G2A, a transcrip- 1993) and target the Rho family GTPase RAC (Skorski et al.,
1998). G2A also modifies cytoskeletal organization and cellulartional target of BCR-ABL, modifies leukemogenesis induced by
this oncoprotein. adhesion by activating RhoA leading to assembly of actin stress
fibers and focal adhesion contacts (Kabarowski et al., 2000).Although G2A function is dispensable for normal T and B
lymphopoiesis throughout young adulthood, G2A-deficient T Coordinate regulation of Rho family GTPases (CDC42, RAC,
RhoA) is critical for the normal regulation of cellular adhesivelymphocytes exhibit hyperproliferative responses in vitro, and
G2A-deficient mice develop a slowly progressive systemic auto- and migratory behavior (Nobes and Hall, 1995; Sander et al.,
1999), suggesting that G2A may modify the leukemogenic po-immune syndrome (Le et al., 2001). While these observations
have supported a role for G2A as a negative regulator of lympho- tency of BCR-ABL by altering cellular migratory/homing or pro-
liferative properties through the concurrent deregulation of RACcyte growth responses, our present studies extend the biologi-
cal context in which this property is manifest to include onco- and RhoA activities.
To address these possibilities, we utilized PET to simultane-genic transformation. G2A is a powerful negative modifier of
P185 BCR-ABL mediated leukemogenesis. Mice transplanted ously examine cellular expansion and migratory characteristics
in individual preleukemic mice. We observed that prior to anywith BCR-ABL transduced G2A-deficient bone marrow cells
exhibit earlier tumor onset, more rapid tumor progression, and indication of overt illness, mice transplanted with G2A-deficient
bone marrow harbor significantly expanded populations of leu-shorter survival times compared to those receiving BCR-ABL
transduced wild-type bone marrow cells. Interestingly, despite kemic cells compared to recipients of wild-type bone marrow.
Figure 5. Overview of PET technique
A: Schematic representation of the protocol for PET imaging of preleukemic mice. SCID mice were transplanted with wild-type total bone marrow cells
infected with MSCV-GFP-IRES-P185 BCR-ABL or MSCV-1sr39TK-IRES-P185 BCR-ABL retroviral stocks. 25 days following transplantation, recipient SCID mice
were administered 200 Ci of [18F] FHBG fluoropenciclovir and subsequently subjected to serial microPET scans dorsoventrally. Representative examples of
microPET scan images of 3 sectional planes a, b, and c from (B) a control leukemic SCID mouse (BCR-ABL alone) and (C) a TK leukemic SCID mouse
(BCR-ABL plus TK). Anatomical landmarks are marked with white broken lines. Following the final scan, mice were X-rayed for identification of anatomical
landmarks. Physiological bowel and renal excretions of the radiolabeled probe represent background and are seen in both control and TK animals.
Signals of TK-labeled tumor cells are detected in the spine, calvarium, and lymph node areas of leukemic animals. Multiple consecutive dorsoventral
sections at the thoracic spine level of a TK leukemic animal are shown in D. The scans are normalized to the individual maximum for each mouse. The
color scale represents the relative intensity from low (Lo) to high (Hi) of positron emission from FHBG.
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Figure 6. Serial microPET images of preleukemic and leukemic mice
SCID mice were transplanted with either wild-type or G2A-deficient total bone marrow cells infected with MSCV-1sr39TK-IRES-P185 BCR-ABL retroviruses and
subjected to microPET scan 9 (A), 16 (B), 23 (C), and 30 (D) days posttransplantation. Representative images at each timepoint are presented. Anatomical
landmarks are marked with white broken lines. Upper panels: coronal sections of microPET images at the spine level of recipients of MSCV-1sr39TK-IRES-
P185 BCR-ABL transduced G2A-deficient (top) and MSCV-1sr39TK-IRES-P185 BCR-ABL transduced wild-type (bottom) bone marrow cells. Middle panels: as
for upper panels, except coronal section is taken at the gastrointestinal level. Lower panels: as for upper panels, except coronal section is taken at the
sternum level. The scans are normalized to the individual maximum for each mouse. The color scale represents the relative intensity from low (Lo) to high
(Hi) of positron emission from FHBG.
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retroviral stock was used to infect bone marrow cells from either G2A-However, the anatomical sites of disease development are simi-
deficient or wild-type mice.lar in all animals, suggesting that the increased mortality of mice
transplanted with BCR-ABL transduced G2A-deficient bone
Bone marrow transformation and in vivo leukemogenesis assay
marrow is likely associated with increased cellular expansion Bone marrow cells were freshly isolated from the tibias and femurs of 4–8
and resultant leukemic burden, rather than altered leukemic week old G2A-deficient or wild-type littermates. Bone marrow cells were
dissemination and organ/tissue involvement. subsequently infected with MSCV-GFP-IRES-BCR-ABL retroviruses and
plated in triplicate in 6 cm dishes as previously described (McLaughlin etG2A exhibits a high degree of homology to several other
al., 1987). The numbers of nonadherent Pre-B cells were counted 7–9 daysGPCRs, most notably TDAG8, GPR4, and OGR1, which are
postinfection.coexpressed in lymphocytes (Choi et al., 1996; Heiber et al.,
For in vivo leukemogenesis assays, 6–8 week old severe combined1995; Xu and Casey, 1996) and share ligand specificities toward
immunodeficient (SCID) mice were sublethally irradiated with 275 rads one
structurally related lysophospholipids (Im et al., 2001; Kabarow- day prior to reconstitution. Whole bone marrow from G2A-deficient or wild-
ski et al., 2001; Xu et al., 2000; Zhu et al., 2001). Interestingly, type littermates was isolated and infected with retroviruses as described
the human genes encoding G2A, TDAG8, and OGR1 are located above. Three hours after infection, bone marrow cells were injected intrave-
nously by tail vein into recipient SCID mice. Animals were monitored dailyon chromosome 14q32, a region in which abnormalities are
for signs of illness for two months as previously described (Afar et al., 1997;frequently found in lymphoid proliferative disorders and lympho-
Lim et al., 2000). For PET imaging of leukemic animals, whole bone marrowmas (Kyaw et al., 1998; Weng et al., 1998). We detect a high
from G2A-deficient or wild-type littermates was infected with MSCV-HSV-
level of G2A mRNA expression in multiple human Ph-positive 1sr39TK-IRES-P185 BCR-ABL retroviral stocks and transplanted into SCID
cell lines (unpublished data). Future studies will address the mice as described above.
question of whether alterations in expression or specific muta-
Histological analysistions, translocation, and/or rearrangements within the G2A lo-
Spleen, bone marrow, and blood were harvested from overtly ill animals andcus are associated with the progression of human Ph-positive
single-cell suspensions from these tissues were depleted of red blood cellslymphoid leukemias.
by hypotonic lysis and cytospun onto microscope slides (Fisher Scientific).In conclusion, G2A functions as a negative modifier of BCR-
Peripheral blood smears and single-cell suspensions from spleen and bone
ABL induced leukemogenesis. By adapting a murine trans- marrow were then analyzed by Giemsa/Wright staining using the HEMA
plantation model of BCR-ABL induced leukemia for microPET solution as per manufacturer’s protocol (Biochemical Sciences, Inc., New
imaging, we have developed a system with the potential to study Jersey).
preleukemic events and resolve the contribution of candidate
RNA and PCR analysiscellular and biological processes otherwise inseparable in ani-
An RT-PCR method was used to measure the G2A RNA levels as previouslymal model systems evaluated by autopsy alone. In this regard,
described (Weng et al., 1998). In brief, total RNA was isolated from either
loss of G2A function primarily affects the early proliferative wild-type or G2A-deficient BCR-ABL-transformed leukemic cells from bone
expansion of B lymphoid cells in the bone marrow. Such models marrow or spleen. First-strand cDNA was synthesized from 5 g of total
should allow more thorough evaluation of therapeutic agents RNA, using the Superscript preamplification system (GIBCO/BRL). Using
G2A-specific primers P1 (TAGCGGTCGCAGGAAATGCAG) and P2 (CAGwith respect to their impact on both cell expansion and sites
GACTGGCTTGGGTCATT), 10% of the first-strand cDNA synthesis productof leukemia development.
was subsequently used for PCR. Glyceraldehyde 3-phosphate dehydroge-
nase (G3PDH) control amplimer set (CLONTECH) was included as a controlExperimental procedures
to ensure equivalent template levels and quality of RNA.
Mice
Cell surface staining and flow cytometric analysisG2A-deficient mice were generated via disruption of the G2A locus by homol-
Single-cell suspensions from spleen, bone marrow and blood, were preparedogous recombination in 129SvJ embryonic stem (ES) cells as previously
as described above and stained with combinations of the following antibod-described (Le et al., 2001). Heterozygotes carrying the G2A null mutation
ies from PharMingen (San Diego, CA), unless otherwise stated: PE-conju-were intercrossed, and offspring were genotyped by Southern blot analysis
gated anti-BP-1, PE-conjugated anti-CD43, PE-conjugated anti-Thy1.2, PE-of tail DNA to identify homozygous mutant mice. All studies reported in this
conjugated anti-Ter119, PE-conjugated anti-Gr1, and Tri-color-conjugatedmanuscript were conducted with mice backcrossed 5 generations onto the
anti-B220 (CALTAG, Burlingame, CA). Data was acquired on a FACScanBALB/c background. C.B-17SCID/SCID mice (Custer et al., 1985) were obtained
(Becton Dickinson) and analyzed using CellQuest software. Live cells werefrom Taconic (Germantown, New York) and housed in isolated barrier facili-
gated based on forward and side scatter (Le et al., 2001).ties containing autoclaved food, water, bedding, and cages. All other animals
were housed in the conventional animal facility at UCLA (Los Angeles, Califor-
PET imagingnia). Animal care and use is in compliance with regulations of the Chancellor’s
9-(4-[18F]-fluoro-3 hydroxymethylbutyl)guanine (FHBG), a substrate for theAnimal Research Committee (ARC) at UCLA.
HSV1-sr39TK enzyme, was synthesized as previously described (Yaghoubi
et al., 2001). At day 9, 16, 23, and 30 posttransplantation, mice were imagedRetroviral vectors and generation of virus stocks
by using the microPET scanner developed at the Crump Institute for Biologi-The retroviral vector pMSCV was used (Hawley et al., 1994). P185 BCR-
cal Imaging (UCLA) (also available through Concorde Microsystems, Knox-ABL cDNA was ligated with the encephalomyocarditis virus Internal Ribo-
ville, TN) (Cherry and Gambhir, 2001). Mice were tail-vein injected with200some Entry Site (IRES) (CLONTECH, Palo Alto, CA) and then cloned into
Ci of FHBG 30 min prior to anesthetization by intraperitoneal injection ofpMSCV. Green Fluorescent Protein (CLONTECH) or HSV-1sr39TK was in-
40 l of a ketamine and xylazine (4:1) solution. Mice were then placed in aserted into pMSCV at a unique EcoRI site between the 3 LTR and IRES-
spread-prone position on a 8  12 cm board and scanned by microPET.P185 BCR-ABL encoding sequences to generate MSCV-GFP-IRES-BCR-
Acquisition time was 56 min (8 min per bed position, seven bed positionsABL and MSCV-1sr39TK-IRES-P185 BCR-ABL, respectively. HSV-1sr39TK
total), and images were reconstructed by using an interative three-dimen-was a gift from Dr. Margaret Black (Washington State University) (Gambhir
sional reconstruction technique as described previously (Qi et al., 1998). Atet al., 2000).
the end of the microPET scan series, animals were sacrificed and detectionRetroviral stocks were prepared by transient cotransfection of 293T
cells with retroviral vectors and Psi ecotropic packaging vector (Muller et of leukemic cells in different organs verified the locations of the signals on
microPET.al., 1991). Supernatants were collected 24–48 hr posttransfection. The same
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